Posted by Michael Wonder on 24 Oct 2018
MS and cholesterol drugs picked for new UK rapid uptake push
24 October 2018 - Accelerated Access Collaborative aims to break down barriers to faster uptake
Rival cholesterol lowering drugs Sanofi's Praluent and Amgen’s Repatha and Merck’s multiple sclerosis treatment Mavenclad have been selected as high priority products for rapid uptake in England.
The medicines have been chosen by the Accelerated Access Collaborative a new initiative aimed at speeding up access to healthcare innovation which could improve patient care and prove to be highly cost effective for England’s NHS.
